Related Topics

    Wang: News Releases & Feature Stories

    Drug reduces hospitalizations and cost of treating young children with sickle cell anemia

    The St. Jude Children’s Research Hospital-led national BABY HUG trial linked hydroxyurea to a 21 percent reduction in annual medical costs for young children with sickle cell anemia; savings expected to grow. (Dr. Winfred Wang)

    How sweet the sound - Elechi Madu

    The results of the Baby HUG study are music to the ears of Emmanuel and Pamela Madu and to other parents of young children with sickle cell anemia.

    Innovative outreach program educates community about sickle cell disease; is national model for such efforts

    The Know Your Sickle Status program, spearheaded by St. Jude Children’s Research Hospital, works with community partners to educate families on trait status for genetic disorder

    Sickle cell anemia drug shown safe and effective for infants and toddlers, improving treatment options

    The multicenter Baby HUG trial led by St. Jude Children’s Research Hospital investigators shows hydroxyurea reduces the most common symptoms of sickle cell anemia in children, raising hopes the drug will ease complications and improve patient quality of life.

    Hope for babies with sickle cell disease

    Through two studies--HUSOFT and BABY HUG--St. Jude is offering hope to babies with sickle cell disease.

    Hydroxyurea safe and effective for sickle cell babies

    Treating babies who have sickle cell anemia (SCA) with oral liquid hydroxyurea appears to prevent the onset of long-term complications triggered by this disease.